CMV Immunity Monitoring in Lung Transplant Recipients

Description

The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.

Conditions

Lung Transplant; Complications

Study Overview

Study Details

Study overview

The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.

Cytomegalovirus T Cell Immunity and Antiviral Prophylaxis Minimization in Lung Transplant Recipients

CMV Immunity Monitoring in Lung Transplant Recipients

Condition
Lung Transplant; Complications
Intervention / Treatment

-

Contacts and Locations

New York

NYU Langone Health, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
  • 2. Pre-existing serological immunity to CMV (R+)
  • 3. Able and willing to provide informed consent
  • 1. Anti-thymocyte globulin induction immunosuppression
  • 2. Perioperative desensitization
  • 3. Pregnant or breastfeeding women

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NYU Langone Health,

Luis Angel, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

2026-09